VWF-containing concentrates in use globally for the treatment of VWD
| Product trade name . | Type . | Availability . | Manufacturer . | VWF:RCo-to-FVIII ratio . | Viral inactivation process . |
|---|---|---|---|---|---|
| Vonvendi/Veyvondi | Recombinant, Chinese hamster ovary cells | North America/Europe | Takeda, United States | rVWF, negligible FVIII | Not applicable |
| Wilfactin/Willfact/Willefact | Plasma derived | Europe | LFB, France | 50 | SD, dry heat (80°C, 72 h), nanofiltration (35 nM) |
| Humate P/Haemate P | Plasma derived | North America/internationally | CSL Behring, Germany | 2.4 | Pasteurization (60°C for 10 h) |
| Voncento | Plasma derived | Europe | CSL Behring, Germany | 2.4 | SD, dry heat (80°C, 72 h) |
| Biostate | Plasma derived | Australia/Asia | CSL Behring, Australia | 2 | SD, dry heat (80°C,72 h) |
| Wilstart | Plasma derived | France | LFB, France | 2 | SD, dry heat (80°C, 72 h), nanofiltration (35 nM) |
| Immunate | Plasma derived | Internationally | Takeda, Austria | 1.1 | SD, vapor heat, 60°C, 10 h at 190 mbar |
| Wilate | Plasma derived | Internationally | Octapharma, Austria | 0.9 | SD, dry heat (100°C, 2 h) |
| Alphanate/Fandhi | Plasma derived | North America/internationally | Grifols, United States | 0.91 | SD, dry heat (80°C, 72 h) |
| Factor 8Y | Plasma derived | Limited European countries | BioProducts Laboratory, England | 0.82 | Dry heat (80°C, 72 h) |
| Product trade name . | Type . | Availability . | Manufacturer . | VWF:RCo-to-FVIII ratio . | Viral inactivation process . |
|---|---|---|---|---|---|
| Vonvendi/Veyvondi | Recombinant, Chinese hamster ovary cells | North America/Europe | Takeda, United States | rVWF, negligible FVIII | Not applicable |
| Wilfactin/Willfact/Willefact | Plasma derived | Europe | LFB, France | 50 | SD, dry heat (80°C, 72 h), nanofiltration (35 nM) |
| Humate P/Haemate P | Plasma derived | North America/internationally | CSL Behring, Germany | 2.4 | Pasteurization (60°C for 10 h) |
| Voncento | Plasma derived | Europe | CSL Behring, Germany | 2.4 | SD, dry heat (80°C, 72 h) |
| Biostate | Plasma derived | Australia/Asia | CSL Behring, Australia | 2 | SD, dry heat (80°C,72 h) |
| Wilstart | Plasma derived | France | LFB, France | 2 | SD, dry heat (80°C, 72 h), nanofiltration (35 nM) |
| Immunate | Plasma derived | Internationally | Takeda, Austria | 1.1 | SD, vapor heat, 60°C, 10 h at 190 mbar |
| Wilate | Plasma derived | Internationally | Octapharma, Austria | 0.9 | SD, dry heat (100°C, 2 h) |
| Alphanate/Fandhi | Plasma derived | North America/internationally | Grifols, United States | 0.91 | SD, dry heat (80°C, 72 h) |
| Factor 8Y | Plasma derived | Limited European countries | BioProducts Laboratory, England | 0.82 | Dry heat (80°C, 72 h) |
SD, solvent detergent.